Xcell Therapeutics Inc. (KOSDAQ:373110)

South Korea · Delayed Price · Currency is KRW

1,169.00

+68.00 (6.18%)

Oct 16, 2026, 3:30 PM KST

Xcell Therapeutics Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	4,357	1,949	1,934	1,124	1,020	1,966
Revenue Growth	193.30%	0.76%	72.11%	10.18%	-48.12%	264.00%
Gross Profit	-1,894	-1,966	-1,399	-1,863	-1,753	-318.08
Operating Income	-11,299	-10,852	-9,330	-8,939	-8,299	-5,705
Net Income	-11,365	-10,927	-9,543	-9,281	-8,342	-9,038
Earnings Per Share	-766.66	-938.00	-954.00	-1049.40	-953.00	-1091.40
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
South Korea	4,094	1,718	1,727	1,089	959.98	1,900
Overseas	262.56	231.23	207.75	34.62	60.06	66.31
Total	4,357	1,949	1,934	1,124	1,020	1,966

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	4,228	6,906	8,802	1,359	5,556	14,632
Total Debt	5,384	5,487	5,702	6,506	5,847	6,191
Net Cash (Debt)	-1,155	1,419	3,100	-5,147	-290.75	8,441
Net Cash Growth	-	-54.22%	-	-	-	378.96%
Net Cash Per Share	-77.92	121.82	309.85	-581.98	-33.21	1019.25

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-10,562	-9,502	-6,996	-6,784	-7,296	-4,605
Capital Expenditures	-172.5	-866.72	-382.69	-224.82	-1,179	-1,347
Free Cash Flow	-10,734	-10,369	-7,379	-7,008	-8,475	-5,952
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	-43.48%	-100.87%	-72.30%	-165.77%	-171.89%	-16.18%
Operating Margin	-259.36%	-556.79%	-482.33%	-795.37%	-813.59%	-290.14%
Pretax Margin	-262.38%	-560.65%	-493.35%	-825.74%	-817.85%	-459.67%
Profit Margin	-260.88%	-560.65%	-493.36%	-825.74%	-817.85%	-459.67%
FCF Margin	-246.39%	-532.01%	-381.48%	-623.58%	-830.82%	-302.69%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 17, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PS Ratio	4.64	14.74	22.95	-	-	-